Autres langues Shionogi & Co., Ltd.

Actions

4507

JP3347200002

Temps Différé Japan Exchange Autres places de cotation 08:00:00 30/05/2024			Varia. 5j.	Varia. 1 janv.
6 976 ^JPY	-0,20 %		+1,42 %	+2,62 %

14/05	L'action japonaise Nikkei se maintient dans une fourchette étroite, dans l'attente des résultats des entreprises locales et des chiffres de l'inflation américaine.	RE
13/05	Le Japonais Shionogi déclare que le traitement COVID n'a pas atteint le critère d'évaluation lors d'un essai de phase avancée	RE

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Japan's Nikkei drifts sideways as more earnings, US CPI awaited	14/05
Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease	13/05
MÄRKTE ASIEN/Börsen wenig verändert - Mazda sehr schwach	13/05
MÄRKTE ASIEN/Uneinheitlich - Anleger meiden Risiken vor US-Preisdaten	13/05
Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial	13/05
Shionogi - Notice of Collaboration Agreement for the Discovery and Development of Novel Malaria Preventive Drugs with Nagasaki University, National Institute of Infectious Diseases, and MMV, Supported by the GHIT Fund	09/05
Akili, Inc. Announces an Amendment to its Strategic Distribution Agreement with Shionogi & Co., Ltd	30/04
Shionogi & Co., Ltd. Revises Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024	25/04
Shionogi & Co., Ltd. - Notice regarding introduction of a Restricted Stock Compensation Plan for Vice Presidents	23/04
Shionogi & Co., Ltd. - Notice Regarding Completion of Cancellation of Treasury Shares	19/04
ESCMID Global 2024, Shionogi presents real-world data demonstrating efficacy of Fetcroja, Fetroja in critically ill patients with certain difficult-to-treat bacterial infections	19/04
Shionogi & Co Completes Cancellation of 10.84 Million Treasury Shares	19/04
Shionogi & Co., Ltd. Announces New Data from the European Real-World Evidence Study of Fetroja®/F etcroja® (cefiderocol)	18/04
Shionogi - The European Commission Grants Orphan Medicinal Product Designation for Zatolmilast, a Potential First-In-Class Treatment Being Investigated for Fragile X Syndrome	12/04
Shionogi Completes Up to 75 Billion Yen Share Buyback	29/03
Tranche Update on Shionogi & Co., Ltd.'s Equity Buyback Plan announced on July 31, 2023.	28/03
Shionogi & Co., Ltd.'s Equity Buyback announced on July 31, 2023, has closed with 10,842,100 shares, representing 3.73% for ¥74,999.22 million.	22/03
FunPep Company Limited announced that it has received ¥199.9998 million in funding from Shionogi & Co., Ltd.	21/03
Shionogi & Co., Ltd. - Recognized as One of the Highest-Ranking Companies on the Supplier Engagement Rating by CDP for the Fourth Consecutive Year	08/03
GSK Unit ViiV Healthcare's Injectable HIV Treatment Shows 'Superior Efficacy' in Late-stage Trial	07/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Shionogi & Co., Ltd.

Actions

4507

JP3347200002

Autres langues

Filtres